APP and Down syndrome: Nonetheless, our data suggest that CMDs may not be a significant additional risk factor for cognitive decline in adults with Down syndrome in the long term, particularly if well managed, in the context of an overwhelming genetic risk for Alzheimer's disease due to amyloid precursor protein (APP) gene triplication, although those with acute presentations may benefit from optimisation of treatment and cognitive surveillance.